Treating HCC: Safety Profile Considerations

Opinion
Video

Tanios S. Bekaii-Saab, MD, discusses safety profile considerations for patients undergoing treatment for hepatocellular carcinoma, and the Oncology Brothers recap the entire discussion.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Related Content
BGB-B2033 is under evaluation for patients with hepatocellular carcinoma who progressed on or after systemic therapy in a first-in-human phase 1 trial.

FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC

Tim Cortese
December 18th 2025
Article

BGB-B2033 is under evaluation for patients with hepatocellular carcinoma who progressed on or after systemic therapy in a first-in-human phase 1 trial.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

MATTERHORN Results Yield Promise in Resectable Gastric/GEJ Cancer

MATTERHORN Results Yield Promise in Resectable Gastric/GEJ Cancer

ONCOLOGY Staff
December 16th 2025
Article

A panel of experts gathered to discuss results from the MATTERHORN trial assessing durvalumab plus FLOT in gastric/GEJ cancer.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The incidence and severity of AEs with eryaspase/chemotherapy was generally consistent with previous reports of chemotherapy alone in advanced PDAC.

Eryaspase Does Not Improve Efficacy vs Chemotherapy Alone in Advanced PDAC

Roman Fabbricatore
December 11th 2025
Article

The incidence and severity of AEs with eryaspase/chemotherapy was generally consistent with previous reports of chemotherapy alone in advanced PDAC.

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Russ Conroy
December 3rd 2025
Article

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.